Ropinirole

證據等級: L5

預測適應症: 10 個

Ropinirole: From Parkinson’s Disease to Attention Deficit-Hyperactivity Disorder

One-Sentence Summary

Ropinirole is a non-ergot dopamine D3/D2 receptor agonist licensed for Parkinson’s disease and restless legs syndrome (RLS), where it compensates for dopaminergic hypofunction in the nigrostriatal and spinal pathways. The TxGNN model predicts it may be effective for Attention Deficit-Hyperactivity Disorder (ADHD), supported by a biologically plausible mechanistic rationale involving mesocortical dopamine deficiency. Currently, no registered clinical trials and 8 publications (predominantly reviews and a single case report) support this repurposing direction, placing the evidence at an early exploratory stage.

Quick Overview

Item	Content
Original Indication	Parkinson’s disease; Restless Legs Syndrome (RLS)
Predicted New Indication	Attention Deficit-Hyperactivity Disorder (ADHD)
TxGNN Prediction Score	99.99%
Evidence Level	L4 (preclinical and mechanistic studies only)
UK Market Status	No MHRA marketing authorisation data retrieved — possible data gap; verify directly with the MHRA Product Licence Register
Number of Marketing Authorisations	0 (per Evidence Pack; see note above)
Recommended Decision	Hold

Data note: Ropinirole (brand names Requip, Adartrel) is widely understood to hold UK marketing authorisations for Parkinson’s disease and RLS. The absence of licence data in this Evidence Pack likely reflects an upstream data retrieval gap rather than a genuine absence of authorisation. Clinicians should verify via the MHRA Product Licence Register before drawing regulatory conclusions.

Why is This Prediction Reasonable?

ADHD is characterised by prefrontal cortical and striatal dopamine hypofunction — particularly reduced activity along the mesocortical D1/D3 receptor pathway — resulting in impaired executive function, attention regulation, and impulse control. Ropinirole is a preferential D3 > D2 dopamine receptor agonist. In theory, its D3 agonism in the prefrontal cortex and nucleus accumbens could partially compensate for the dopaminergic deficit underlying ADHD’s inattentive and cognitive symptom dimensions, analogous to how methylphenidate and amphetamines act, albeit through a different mechanism (reuptake inhibition rather than direct receptor agonism).

A compelling indirect line of support comes from the well-documented comorbidity between RLS and ADHD. Both conditions share an iron-dopamine deficiency hypothesis: reduced central iron availability leads to impaired dopamine synthesis, manifesting as motor restlessness in RLS and attentional dysregulation in ADHD. Published literature — including a case report of ropinirole improving both RLS and ADHD symptoms in a child — provides proof-of-concept for the shared pathophysiology.

However, a critical safety caveat applies: ropinirole’s D2 agonist activity in the mesolimbic system could theoretically exacerbate impulsivity or promote reward-related behavioural dysregulation in susceptible individuals. This pharmacodynamic duality means any future clinical investigation would require careful patient selection and monitoring.

MOA data note: Formal mechanism of action data was not captured in this Evidence Pack. The above mechanistic rationale is derived from published pharmacological literature and should be confirmed against the current SmPC prior to any clinical planning.

Clinical Trial Evidence

Currently no related clinical trials registered (ClinicalTrials.gov, ISRCTN, and WHO ICTRP searches returned zero results for Ropinirole + ADHD).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15866437	2005	Case Report	Pediatric Neurology	A 6-year-old with ADHD and RLS/PLMS showed significant improvement in both ADHD symptoms and sleep following ropinirole treatment; methylphenidate alone had been insufficient
16218085	2005	Narrative Review	Sleep	Comprehensive review of RLS–ADHD comorbidity; discusses shared iron/dopamine deficiency hypothesis and potential for common pharmacological treatments including dopamine agonists
34182128	2021	In Vitro / Mechanistic	Pharmacological Research	DRD4 polymorphisms (particularly DRD4.7, associated with ADHD) form heteromers with α2A adrenoceptors, modulating dopamine signalling; suggests D4/D3 receptor crosstalk relevant to ADHD pharmacology
17483695	2007	Animal Study	J Neuropathol Exp Neurol	A11 nucleus dopamine lesions combined with iron deprivation in mice increase locomotor activity, supporting the iron-dopamine animal model for RLS and the shared neurobiological substrate with ADHD
18656214	2008	Review	Revue Neurologique	Overview of RLS epidemiology, pathophysiology (iron/dopamine system), and treatment; contextualises the dopaminergic deficit relevant to both RLS and ADHD comorbidity
24992083	2014	Clinical Study (RCT)	Clinical Neuropharmacology	Randomised comparison of piribedil, pramipexole, and ropinirole in Parkinson’s disease patients with excessive daytime sleepiness; demonstrates ropinirole’s differential cognitive and vigilance profile versus other D2/D3 agonists
30950895	2019	Adverse Event Report	Cornea	Corneal oedema reported in 3 patients on systemic dopaminergic agents; relevant safety signal for ophthalmic monitoring during dopamine agonist therapy
30460371	2019	Case Report	Acta Dermato-Venereologica	Treatment-induced delusions of infestation associated with elevated brain dopamine levels; highlights neuropsychiatric risk of dopaminergic overstimulation relevant to any psychiatric repurposing context

UK Market Information

No MHRA marketing authorisation data was retrieved for Ropinirole in this Evidence Pack (0 licences recorded). This is inconsistent with the known regulatory status of the drug and likely represents a data retrieval gap in the current pipeline.

Clinicians should consult the following authoritative UK sources directly:

MHRA Product Licence Register — search for “Ropinirole” or “Requip” / “Adartrel”
BNF (British National Formulary) — BNF section 4.9.1 (Dopaminergic drugs used in Parkinson’s disease) and section 4.6 (Antiemetics and related drug classes)
NICE Technology Appraisals — for approved indications and prescribing guidance

Safety Considerations

Formal MHRA summary of product characteristics (SmPC) data and contraindication data were not available in this Evidence Pack.

Please refer to the SmPC and BNF for full safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Clinically important consideration for the ADHD repurposing context: Based on the published literature retrieved, the following safety signals are worth flagging proactively:

Impulse control disorders (pathological gambling, hypersexuality, compulsive eating) are a known class effect of dopamine agonists and would be of particular concern in an ADHD population already predisposed to impulsivity.

Neuropsychiatric effects including hallucinations and delusions have been reported with dopaminergic agents; these warrant careful monitoring if use in psychiatric populations is ever explored.

Excessive daytime somnolence and sudden-onset sleep are established class effects relevant to paediatric and occupational safety.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic hypothesis linking ropinirole’s D3/D2 agonism to ADHD’s dopaminergic deficiency is biologically plausible and supported by the RLS–ADHD comorbidity literature; however, the evidence base consists solely of a single paediatric case report and indirect mechanistic studies (Evidence Level L4), with no registered clinical trials. Significant safety concerns — particularly impulse control disorders and potential worsening of hyperactivity/impulsivity via mesolimbic D2 stimulation — constitute substantial barriers to clinical progression without further preclinical de-risking.

To proceed, the following is needed:

Formal MOA confirmation: Retrieve full DrugBank and SmPC mechanistic data for ropinirole, including receptor binding profiles (Ki values for D2 vs D3 vs D1) to quantify selectivity relevant to ADHD subtypes
Preclinical ADHD model data: Systematic review of dopamine D3 agonist effects in validated ADHD animal models (e.g., spontaneously hypertensive rat, DAT-knockdown models) before any clinical hypothesis can be tested
MHRA licence data retrieval: Resolve the UK marketing authorisation data gap by querying the MHRA Product Licence Register directly; confirm approved indications, current SmPC warnings, and contraindications
Safety review for psychiatric populations: Conduct a structured review of impulse control disorder risk from ropinirole’s regulatory safety data (PSUR/DSUR) as this is a Blocking concern for any ADHD trial design
Paediatric considerations: Given the predominantly paediatric ADHD population, a dedicated assessment of ropinirole’s paediatric pharmacokinetic and safety profile (ICH E11 framework) would be required before any investigational use

This report is generated for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application. All regulatory and prescribing decisions should reference current MHRA-approved product information.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.